Med-Mastodon

NonilexBefore the case was narrowed to the <a href="https://masto.ai/tags/AppointmentsClause" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#AppointmentsClause</a> issue, the lawsuit included a <a href="https://masto.ai/tags/religious" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#religious</a> objection to being required to cover pre-exposure <a href="https://masto.ai/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> for <a href="https://masto.ai/tags/HIV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HIV</a>. They claimed that such drugs "facilitate & encourage homosexual behavior, prostitution, sexual promiscuity & intravenous drug use."<a href="https://masto.ai/tags/law" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#law</a> <a href="https://masto.ai/tags/SCOTUS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SCOTUS</a> <a href="https://masto.ai/tags/medicine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#medicine</a> <a href="https://masto.ai/tags/HealthCare" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HealthCare</a> <a href="https://masto.ai/tags/ACA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#ACA</a> <a href="https://masto.ai/tags/insurance" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#insurance</a> <a href="https://masto.ai/tags/PreventiveCare" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PreventiveCare</a>

Victoria Stuart 🇨🇦 🏳️‍⚧️Lenacapavir: this annual shot might protect against HIV infections <a href="https://www.technologyreview.com/2025/03/14/1113225/annual-shot-protect-against-hiv" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.technologyreview.com/2025/03/14/1113225/annual-shot-protect-against-hiv</a>[Dec 2024] Drug lenacapavir 'breakthrough of year.' Could end HIV epidemic <a href="https://mastodon.social/@persagen/113643639851357794" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://mastodon.social/@persagen/113643639851357794</a> <a href="https://en.wikipedia.org/wiki/Lenacapavir" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://en.wikipedia.org/wiki/Lenacapavir</a>Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.Comment: the value of basic science/biomedical research cannot be emphasized enough.<a href="https://mastodon.social/tags/HIV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HIV</a> <a href="https://mastodon.social/tags/AIDS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#AIDS</a> <a href="https://mastodon.social/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> <a href="https://mastodon.social/tags/lenacapavir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#lenacapavir</a> <a href="https://mastodon.social/tags/GileadScience" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#GileadScience</a> <a href="https://mastodon.social/tags/PURPOSE1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PURPOSE1</a> <a href="https://mastodon.social/tags/PURPOSE2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PURPOSE2</a> studies

Giuseppe MichieliEvaluation of <a href="https://mstdn.science/tags/influenza" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#influenza</a> <a href="https://mstdn.science/tags/antiviral" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antiviral</a> <a href="https://mstdn.science/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> for long-term care residents: a systematic review and meta-analysis, <a href="https://etidiohnew.blogspot.com/2025/03/evaluation-of-influenza-antiviral.html" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://etidiohnew.blogspot.com/2025/03/evaluation-of-influenza-antiviral.html</a>

Giuseppe MichieliPre-exposure <a href="https://mstdn.science/tags/antibody" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antibody</a> <a href="https://mstdn.science/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> protects <a href="https://mstdn.science/tags/macaques" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#macaques</a> from severe <a href="https://mstdn.science/tags/influenza" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#influenza</a>, <a href="https://etidiohnew.blogspot.com/2025/01/pre-exposure-antibody-prophylaxis.html" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://etidiohnew.blogspot.com/2025/01/pre-exposure-antibody-prophylaxis.html</a>

Victoria Stuart 🇨🇦 🏳️‍⚧️Drug lenacapavir 'breakthrough of year.' Could end HIV epidemic <a href="https://www.npr.org/sections/goats-and-soda/2024/12/12/g-s1-37662/breakthrough-hiv-lenacapavir" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.npr.org/sections/goats-and-soda/2024/12/12/g-s1-37662/breakthrough-hiv-lenacapavir</a>* 1.3M new HIV infect./yr globally * U.N. goal: end HIV/AIDS by 2030 * 2 groundbreaking clinical trials * drug lenacapavir virt. elim. new HIV infections thru sex * Science j. 2024 Breakthrough of Year * admin. via 2x yearly injectionLenacapavir: <a href="https://en.wikipedia.org/wiki/Lenacapavir" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://en.wikipedia.org/wiki/Lenacapavir</a>Epidemiology of HIV/AIDS <a href="https://en.wikipedia.org/wiki/Epidemiology_of_HIV/AIDS" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://en.wikipedia.org/wiki/Epidemiology_of_HIV/AIDS</a><a href="https://mastodon.social/tags/HIV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HIV</a> <a href="https://mastodon.social/tags/AIDS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#AIDS</a> <a href="https://mastodon.social/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> <a href="https://mastodon.social/tags/lenacapavir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#lenacapavir</a> <a href="https://mastodon.social/tags/GileadScience" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#GileadScience</a> <a href="https://mastodon.social/tags/PURPOSE1" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PURPOSE1</a> <a href="https://mastodon.social/tags/PURPOSE2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PURPOSE2</a> studies

N95Bias Ⓥ🏴‍☠️I repeat: hypochlorous acid is a miracle. HOCl solution can apparently be nebulized and inhaled as a prophylactic (CW: animal testing)"In this report, we establish through independent laboratories that the SARS-CoV-2 virus is rapidly inactivated by exposure to HOCl, as is poliovirus – a far more difficult virus to inactivate and often the gold standard for virucidal assessment. Inhalation of a microaerosolized fog of that same virucidal HOCl solution by rodents using the US EPA’s acute 4-hour inhalation toxicity protocol later provided observational, physiological, gross pathological, and histopathological evidence that showed pulmonary exposure of 52ppm HOCl to respiratory epithelium did not result in any difference when compared to control animals. Also reported are the chemical and antimicrobial characterizations of the HOCl microaerosols reportedly used as SARS-CoV-2 prophylaxis within the United States and elsewhere during the pandemic lockdown."This also implies that you could stick it in a humidifier and disinfect the air of a space that someone infectious may have recently left, in addition to (or as an alternative to, if unavailable) air filtration<a href="https://fortuneonline.org/articles/inhalation-of-microaerosolized-hypochlorous-acid-hocl-biochemical-antimicrobial-and-pathological-assessment.html" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://fortuneonline.org/articles/inhalation-of-microaerosolized-hypochlorous-acid-hocl-biochemical-antimicrobial-and-pathological-assessment.html</a><a href="https://zeroes.ca/tags/SARSCoV2" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARSCoV2</a> <a href="https://zeroes.ca/tags/covid" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#covid</a> <a href="https://zeroes.ca/tags/covid19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#covid19</a> <a href="https://zeroes.ca/tags/prophylactic" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylactic</a> <a href="https://zeroes.ca/tags/prophylactics" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylactics</a> <a href="https://zeroes.ca/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> <a href="https://zeroes.ca/tags/PublicHealth" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PublicHealth</a> <a href="https://zeroes.ca/tags/CovidIsNotOver" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#CovidIsNotOver</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Emergency" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Emergency</a> <a href="https://mstdn.science/tags/Use" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Use</a> <a href="https://mstdn.science/tags/Instructions" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Instructions</a> (<a href="https://mstdn.science/tags/EUI" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#EUI</a>) for <a href="https://mstdn.science/tags/Oseltamivir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Oseltamivir</a>, <a href="https://mstdn.science/tags/US" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#US</a> <a href="https://mstdn.science/tags/CDC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#CDC</a>: <a href="https://www.cdc.gov/bird-flu/hcp/emergency-use-oseltamivir/index.html" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.cdc.gov/bird-flu/hcp/emergency-use-oseltamivir/index.html</a> What to know: On July 19, 2024, CDC issued Emergency Use Instructions (EUI) for an <a href="https://mstdn.science/tags/antiviral" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antiviral</a> called oseltamivir, generic for brand name drug <a href="https://mstdn.science/tags/Tamiflu" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Tamiflu</a>, for <a href="https://mstdn.science/tags/treatment" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#treatment</a> or post-exposure <a href="https://mstdn.science/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> (<a href="https://mstdn.science/tags/PEP" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PEP</a>) of <a href="https://mstdn.science/tags/pandemic" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#pandemic</a> <a href="https://mstdn.science/tags/influenza" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#influenza</a> A viruses and novel influenza A viruses with pandemic potential.

Giuseppe MichieliOral <a href="https://mstdn.science/tags/Nirmatrelvir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Nirmatrelvir</a>–Ritonavir as <a href="https://mstdn.science/tags/Postexposure" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Postexposure</a> <a href="https://mstdn.science/tags/Prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Prophylaxis</a> for <a href="https://mstdn.science/tags/Covid19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Covid19</a>, N Engl J Med.: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2309002" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.nejm.org/doi/full/10.1056/NEJMoa2309002</a> In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir–ritonavir for 5 or 10 days did not significantly reduce the <a href="https://mstdn.science/tags/risk" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#risk</a> of symptomatic <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.)

Matt WillemsenHIV prevention drug found 100% effective in clinical trial <a href="https://www.livescience.com/health/hiv/hiv-prevention-drug-found-100-effective-in-clinical-trial" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.livescience.com/health/hiv/hiv-prevention-drug-found-100-effective-in-clinical-trial</a> <a href="https://mastodon.social/tags/health" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#health</a> <a href="https://mastodon.social/tags/HIV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HIV</a> <a href="https://mastodon.social/tags/prevention" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prevention</a> <a href="https://mastodon.social/tags/ClinicalTrial" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#ClinicalTrial</a> <a href="https://mastodon.social/tags/lenacapavir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#lenacapavir</a> <a href="https://mastodon.social/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> <a href="https://mastodon.social/tags/PrEP" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PrEP</a> <a href="https://mastodon.social/tags/GileadSciences" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#GileadSciences</a>

Giuseppe Michieli<a href="https://mstdn.science/tags/Antivirals" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Antivirals</a> for <a href="https://mstdn.science/tags/PEP" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#PEP</a> of <a href="https://mstdn.science/tags/influenza" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#influenza</a>: a systematic <a href="https://mstdn.science/tags/review" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#review</a> and network meta-analysis, MedRxIV, <a href="https://www.medrxiv.org/content/10.1101/2024.05.28.24307995v1" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://www.medrxiv.org/content/10.1101/2024.05.28.24307995v1</a> Post-exposure <a href="https://mstdn.science/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> with <a href="https://mstdn.science/tags/zanamivir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#zanamivir</a>, <a href="https://mstdn.science/tags/oseltamivir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#oseltamivir</a>, <a href="https://mstdn.science/tags/laninamivir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#laninamivir</a> or <a href="https://mstdn.science/tags/baloxavir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#baloxavir</a> might reduce the <a href="https://mstdn.science/tags/risk" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#risk</a> of symptomatic <a href="https://mstdn.science/tags/zoonotic" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#zoonotic</a> influenza after exposure to novel influenza A viruses associated with severe disease in infected humans.

Giuseppe Michieli<a href="https://mstdn.science/tags/Epitopes" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Epitopes</a> of an <a href="https://mstdn.science/tags/antibody" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antibody</a> that neutralizes a wide range of <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/variants" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#variants</a> in a conserved subdomain 1 of the <a href="https://mstdn.science/tags/spike" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#spike</a> protein, J Virol.: <a href="https://journals.asm.org/doi/full/10.1128/jvi.00416-24?af=R" rel="nofollow noopener noreferrer" translate="no" target="_blank">https://journals.asm.org/doi/full/10.1128/jvi.00416-24?af=R</a> Demonstrated identification of the neutralizing antibody that recognizes a conserved epitope implies basal contribution of such group of antibodies for <a href="https://mstdn.science/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> against <a href="https://mstdn.science/tags/COVID19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#COVID19</a>.

ECDCRT by <a href="https://respublicae.eu/@ECDC_EU" class="u-url mention" rel="nofollow noopener noreferrer" target="_blank">@ECDC_EU</a>: Check out our new issue with early data on effectiveness of monoclonal antibody against Respiratory syncytial virus <a href="https://respublicae.eu/tags/RSV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#RSV</a> from 🇪🇸🗞️<a href="https://bit.ly/EUS296" rel="nofollow noopener noreferrer" target="_blank">https://bit.ly/EUS296</a><a href="https://respublicae.eu/tags/children" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#children</a> <a href="https://respublicae.eu/tags/immunisation" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#immunisation</a> <a href="https://respublicae.eu/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> <a href="https://respublicae.eu/tags/CCHF" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#CCHF</a> <a href="https://respublicae.eu/tags/vectors" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#vectors</a> <a href="https://respublicae.eu/tags/Cdiff" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Cdiff</a> <a href="https://respublicae.eu/tags/encephalitis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#encephalitis</a> <a href="https://respublicae.eu/tags/HIV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#HIV</a> <a href="https://respublicae.eu/tags/publichealth" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#publichealth</a> 🐦🔗: <a href="https://nitter.cz/Eurosurveillanc/status/1755871682672120260#m" rel="nofollow noopener noreferrer" target="_blank">https://nitter.cz/Eurosurveillanc/status/1755871682672120260#m</a>[2024-02-09 08:30 UTC]

DamonHDI meant "slightly annoying but useful <a href="https://mastodon.social/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a>", obvs.

Gabriele PollaraLess is more - don't add Vancomycin unless you need to in surgical prophylaxis.(better, use teicoplanin, but many countries don't have it!)<a href="https://med-mastodon.com/tags/AMR" class="mention hashtag" rel="tag">#AMR</a> <a href="https://med-mastodon.com/tags/antibiotics" class="mention hashtag" rel="tag">#antibiotics</a> <a href="https://med-mastodon.com/tags/IDMastodon" class="mention hashtag" rel="tag">#IDMastodon</a> <a href="https://med-mastodon.com/tags/infectiousdiseases" class="mention hashtag" rel="tag">#infectiousdiseases</a> <a href="https://med-mastodon.com/tags/medicine" class="mention hashtag" rel="tag">#medicine</a> <a href="https://med-mastodon.com/tags/surgery" class="mention hashtag" rel="tag">#surgery</a> <a href="https://med-mastodon.com/tags/prophylaxis" class="mention hashtag" rel="tag">#prophylaxis</a> <a href="https://med-mastodon.com/tags/MRSA" class="mention hashtag" rel="tag">#MRSA</a>Trial of Vancomycin and Cefazolin as Surgical Prophylaxis in Arthroplasty<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2301401?query=TOC&cid=NEJM%20eToc,%20October%2019,%202023%20DM2292852_NEJM_Non_Subscriber&bid=1868113537" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://www.nejm.org/doi/full/10.1056/NEJMoa2301401?query=TOC&cid=NEJM%20eToc,%20October%2019,%202023%20DM2292852_NEJM_Non_Subscriber&bid=1868113537</a>

Giuseppe MichieliImpaired neutralizing <a href="https://mstdn.science/tags/antibody" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antibody</a> <a href="https://mstdn.science/tags/efficacy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#efficacy</a> of <a href="https://mstdn.science/tags/tixagevimab" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#tixagevimab</a>-cilgavimab 150+150 mg as pre-exposure <a href="https://mstdn.science/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> against <a href="https://mstdn.science/tags/Omicron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Omicron</a> <a href="https://mstdn.science/tags/BA5" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#BA5</a>. A real-world experience in booster vaccinated immunocompromised patients, J Clin Virol.: <a href="https://doi.org/10.1016/j.jcv.2023.105584" rel="nofollow noopener noreferrer" target="_blank">https://doi.org/10.1016/j.jcv.2023.105584</a> <a href="https://mstdn.science/tags/reseach" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#reseach</a> <a href="https://mstdn.science/tags/science" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#science</a> <a href="https://mstdn.science/tags/medicine" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#medicine</a> <a href="https://mstdn.science/tags/mAbs" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#mAbs</a> <a href="https://mstdn.science/tags/betacoronavirus" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#betacoronavirus</a> <a href="https://mstdn.science/tags/sarbecovirus" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#sarbecovirus</a> <a href="https://mstdn.science/tags/covid19" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#covid19</a>

Giuseppe MichieliCox, R.M., Lieber, C.M., Wolf, J.D. et al. Comparing <a href="https://mstdn.science/tags/molnupiravir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#molnupiravir</a> and <a href="https://mstdn.science/tags/nirmatrelvir" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#nirmatrelvir</a>/ritonavir <a href="https://mstdn.science/tags/efficacy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#efficacy</a> and the effects on <a href="https://mstdn.science/tags/SARS" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#SARS</a>-CoV-2 <a href="https://mstdn.science/tags/transmission" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#transmission</a> in animal <a href="https://mstdn.science/tags/models" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#models</a>. Nat Commun 14, 4731 (2023). <a href="https://doi.org/10.1038/s41467-023-40556-8" rel="nofollow noopener noreferrer" target="_blank">https://doi.org/10.1038/s41467-023-40556-8</a> <a href="https://mstdn.science/tags/research" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#research</a> <a href="https://mstdn.science/tags/science" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#science</a> <a href="https://mstdn.science/tags/antivirals" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antivirals</a> <a href="https://mstdn.science/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a>

Manni_P :mastolove:<a href="https://www.endocrine.org/topics/edc" rel="nofollow noopener noreferrer" target="_blank">https://www.endocrine.org/topics/edc</a> vs <a href="https://troet.cafe/tags/Patent6630507" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Patent6630507</a><a href="https://troet.cafe/tags/Cannabis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#Cannabis</a> as <a href="https://troet.cafe/tags/antioxidants" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#antioxidants</a> and <a href="https://troet.cafe/tags/neuroprotectants" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#neuroprotectants</a> <a href="https://troet.cafe/tags/weedmob" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#weedmob</a> Feb 2, 2001 - The United States as represented by the Department of Health and Human ServicesCannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the <a href="https://troet.cafe/tags/treatment" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#treatment</a> and <a href="https://troet.cafe/tags/prophylaxis" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#prophylaxis</a> of wide variety of <a href="https://troet.cafe/tags/oxidation" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#oxidation</a> <a href="https://troet.cafe/tags/associated" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#associated</a> <a href="https://troet.cafe/tags/diseases" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#diseases</a>, such as ischemic, age-related, inflammatory autoimmune diseases.

Gabriele PollaraInclusion of fosfomycin in prophylaxis guideline (single centre data), big reduction in total antibiotic use <a href="https://med-mastodon.com/tags/urology" class="mention hashtag" rel="tag">#urology</a> <a href="https://med-mastodon.com/tags/prophylaxis" class="mention hashtag" rel="tag">#prophylaxis</a> <a href="https://med-mastodon.com/tags/UTI" class="mention hashtag" rel="tag">#UTI</a> <a href="https://med-mastodon.com/tags/ECCMID2023" class="mention hashtag" rel="tag">#ECCMID2023</a>

Gabriele PollaraImportance discordances in the indication and duration of antibiotic prophylaxis for urological surgery <a href="https://med-mastodon.com/tags/AMS" class="mention hashtag" rel="tag">#AMS</a> <a href="https://med-mastodon.com/tags/AMR" class="mention hashtag" rel="tag">#AMR</a> <a href="https://med-mastodon.com/tags/urology" class="mention hashtag" rel="tag">#urology</a> <a href="https://med-mastodon.com/tags/prophylaxis" class="mention hashtag" rel="tag">#prophylaxis</a> <a href="https://med-mastodon.com/tags/ECCMID2023" class="mention hashtag" rel="tag">#ECCMID2023</a>

Gabriele PollaraAdherence (or lack of) to surgical antibiotic prophylaxis guidelines will always depend on lots of local factors.Neverthelsss, headline figure (59% 👎) and scale of these data (825 hospitals & 521,091 surgeries) is impressive! <a href="https://med-mastodon.com/tags/IDMastodon" class="mention hashtag" rel="tag">#IDMastodon</a> <a href="https://med-mastodon.com/tags/MedMastodon" class="mention hashtag" rel="tag">#MedMastodon</a> <a href="https://med-mastodon.com/tags/AMR" class="mention hashtag" rel="tag">#AMR</a> <a href="https://med-mastodon.com/tags/antibiotics" class="mention hashtag" rel="tag">#antibiotics</a> <a href="https://med-mastodon.com/tags/prophylaxis" class="mention hashtag" rel="tag">#prophylaxis</a> <a href="https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciad077/7034632#.Y-kJ39B4VvI.twitter" target="_blank" rel="nofollow noopener noreferrer" translate="no">https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciad077/7034632#.Y-kJ39B4VvI.twitter</a>

Recent searches

Search options

Administered by:

Server stats:

#prophylaxis